These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 20452894)
21. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Sulkowski MS; Fessel WJ; Lazzarin A; Berenguer J; Zakharova N; Cheinquer H; Côté P; Dieterich D; Gadano A; Matthews G; Molina JM; Moreno C; Pineda JA; Pulido F; Rivero A; Rockstroh J; Hernandez D; McPhee F; Eley T; Liu Z; Mendez P; Hughes E; Noviello S; Ackerman P Hepatol Int; 2017 Mar; 11(2):188-198. PubMed ID: 28210927 [TBL] [Abstract][Full Text] [Related]
22. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. Núñez M; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de Los Santos I; San Joaquín I; Echeverría S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola JM; Romero M; García-Samaniego J; Soriano V; AIDS Res Hum Retroviruses; 2007 Aug; 23(8):972-82. PubMed ID: 17725413 [TBL] [Abstract][Full Text] [Related]
23. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550 [TBL] [Abstract][Full Text] [Related]
24. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients]. Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [TBL] [Abstract][Full Text] [Related]
26. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy]. Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760 [TBL] [Abstract][Full Text] [Related]
27. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434 [TBL] [Abstract][Full Text] [Related]
28. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B; J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005 [TBL] [Abstract][Full Text] [Related]
30. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection. Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734 [TBL] [Abstract][Full Text] [Related]
31. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
32. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. Sulkowski MS; Felizarta F; Smith C; Slim J; Berggren R; Goodman R; Ball L; Khalili M; Dieterich DT; J Acquir Immune Defic Syndr; 2004 Apr; 35(5):464-72. PubMed ID: 15021311 [TBL] [Abstract][Full Text] [Related]
33. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150 [TBL] [Abstract][Full Text] [Related]
35. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes. Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679 [TBL] [Abstract][Full Text] [Related]
36. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J; PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696 [TBL] [Abstract][Full Text] [Related]
37. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G; J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482 [TBL] [Abstract][Full Text] [Related]
38. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin. Nasti G; Di Gennaro G; Tavio M; Cadorin L; Tedeschi RM; Talamini R; Carbone A; Tirelli U AIDS; 2001 Sep; 15(14):1783-7. PubMed ID: 11579239 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Santin M; Shaw E; Garcia MJ; Delejido A; de Castro ER; Rota R; Altés J; Baguena F; Valero S; Sala M; Casanova A; AIDS Res Hum Retroviruses; 2006 Apr; 22(4):315-20. PubMed ID: 16623633 [TBL] [Abstract][Full Text] [Related]
40. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J; AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]